vasoactive-intestinal-peptide and Abdominal-Pain

vasoactive-intestinal-peptide has been researched along with Abdominal-Pain* in 4 studies

Other Studies

4 other study(ies) available for vasoactive-intestinal-peptide and Abdominal-Pain

ArticleYear
Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome.
    Gut and liver, 2016, May-23, Volume: 10, Issue:3

    Previous studies have revealed that mast cells (MCs) may activate the protease-activated receptors and release of neuropeptides involved in the pathogenesis of irritable bowel syndrome (IBS). The levels of proteaseactivated receptor 2 (PAR-2) and tryptase can contribute to understanding the pathogenesis of IBS.. Colonoscopic biopsies were performed of 38 subjects (20 with IBSdiarrhea [IBS-D], eight with IBS-constipation [IBS-C], and 10 healthy volunteers). The mRNA and protein levels of tryptase and PAR-2 were assessed by real-time PCR and Western blot. The levels of vasoactive intestinal peptide (VIP), substance P (SP), and calcitonin gene-related peptide (CGRP) were measured by immunohistochemistry, and MCs were counted by toluidine blue staining.. Significant increases in the mRNA expression of tryptase (p<0.05, IBS-D, IBS-C vs control) and PAR-2 (p<0.05, IBS-D, IBS-C vs control) and in the tryptase protein level (p<0.05, IBS-D, IBS-C vs control) were detected in IBS. Elevations of MCs, CGRP, VIP and SP (p<0.05, IBS-D vs control) were observed for IBS-D only.. Tryptase levels may upregulate the function of PAR- 2, resulting in the release of neuropeptide and they were correlated with clinical symptoms associated with IBS.

    Topics: Abdominal Pain; Adult; Calcitonin Gene-Related Peptide; Case-Control Studies; Colon; Female; Humans; Irritable Bowel Syndrome; Male; Mast Cells; Middle Aged; Receptor, PAR-2; RNA, Messenger; Substance P; Tryptases; Vasoactive Intestinal Peptide

2016
Childhood chronic gastritis and duodenitis: Role of altered sensory neuromediators.
    World journal of gastroenterology, 2016, Oct-07, Volume: 22, Issue:37

    To investigate the roles of the neuropeptides vasoactive intestinal peptide (VIP), substance P (SP), and calcitonin gene-related peptide (CGRP) in chronic gastritis and duodenitis in children.. Biopsy samples from the gastric and duodenal mucosa of 52 patients and 30 control subjects were obtained. Samples were taken for pathological examination, immunohistochemical staining, enzyme activity measurements and quantitative measurements of tissue peptide levels.. We observed differential effects of the disease on peptide levels, which were somewhat different from previously reported changes in chronic gastritis in adults. Specifically, SP was increased and CGRP and VIP were decreased in patients with gastritis. The changes were more prominent at sites where gastritis was severe, but significant changes were also observed in neighboring areas where gastritis was less severe. Furthermore, the degree of changes was correlated with the pathological grade of the disease. The expression of CD10, the enzyme primarily involved in SP hydrolysis, was also decreased in patients with duodenitis.. Based on these findings, we propose that decreased levels of VIP and CGRP and increased levels of SP contribute to pathological changes in gastric mucosa. Hence, new treatments targeting these molecules may have therapeutic and preventive effects.

    Topics: Abdominal Pain; Adolescent; Calcitonin Gene-Related Peptide; Case-Control Studies; Child; Duodenitis; Endoscopy; Female; Gastric Mucosa; Gastritis; Humans; Hydrolysis; Immunohistochemistry; Male; Neprilysin; Neuropeptides; Substance P; Vasoactive Intestinal Peptide

2016
Neuroimmune appendicitis.
    Lancet (London, England), 1999, Aug-07, Volume: 354, Issue:9177

    15-25% of appendices removed from patients with suspected appendicitis appear normal on histological examination. The cause of pain in such patients is unknown. Since the content of neuropeptides seems to be altered in chronic inflammation, we investigated possible changes in peptidergic innervation for substance P (SP), vasoactive intestinal peptide (VIP), and growth-associated protein-43 (GAP-43).. Appendices classified as showing acute appendicitis, non-acute appendicitis (clinical signs of acute appendicitis, but histologically not inflamed), or normal were processed for SP, VIP, and GAP-43 immunocytochemistry. The density of SP immunostaining was assessed by digitised morphometry.. 31 appendix specimens were studied (16 acute, 15 non-acute). 16 specimens were used as controls. Expression of GAP-43 was increased in the non-acute appendices. We observed larger amounts of SP-immunoreactive and VIP-immunoreactive nerves in the mucosal layer of the appendix in patients with non-acute appendicitis than in controls and patients with acute appendicitis (mean % area SP-immunoreactive 0.0496 [SD 0.0113] non-acute, 0.0221 [0.0049] acute, 0.0229 [0.0068] controls). In addition, a close spatial relation between SP-immunoreactive and VIP-immunoreactive nerve fibres and lymphoid cells was detected in the outer zone of lymph follicles.. Neuroproliferation in the appendix, in association with an increase in neurotransmitters SP and VIP, may be involved in the pathophysiology of acute right abdominal pain in the absence of an acute inflammation of the appendix. Our data, together with increasing knowledge about the way in which the nervous system and immune cells interact, suggest that neuroimmune appendicitis is a distinct pathological entity.

    Topics: Abdominal Pain; Acute Disease; Adolescent; Adult; Aged; Appendectomy; Appendicitis; Appendix; Diagnosis, Differential; Enteric Nervous System; Female; GAP-43 Protein; Humans; Immunoenzyme Techniques; Lymphoid Tissue; Male; Middle Aged; Neuronal Plasticity; Prospective Studies; Substance P; Vasoactive Intestinal Peptide

1999
Neuroimmune appendicitis, peptides, and schizophrenia.
    Lancet (London, England), 1999, Nov-06, Volume: 354, Issue:9190

    Topics: Abdominal Pain; Appendicitis; Arthritis, Rheumatoid; Comorbidity; Finland; Humans; Prevalence; Schizophrenia; Vasoactive Intestinal Peptide

1999